What is Janoshik testing and how do I verify a report?

Janoshik Analytical is an independent third-party laboratory that analyses research compounds — peptides among them — and issues an analytical report for the specific sample it received. It is not a regulator, a certifying body, or a quality seal you can buy; it is a lab that measures what was in one vial and documents the result. To verify a report, work in three steps: confirm the document is authentic by resolving its report or test identifier through the lab's own verification system rather than the seller's site, confirm it corresponds to the exact batch number on the product you are being offered, and confirm the figures on it actually support the claim the seller is making. A report that fails any one of those three checks tells you nothing useful, no matter how professional the PDF looks.

For a business buyer — a med spa owner, a clinic operator, a telehealth founder, a reseller building a catalog — this is one of the few supplier-vetting tasks you can complete yourself, in a few minutes, without taking anyone's word for anything. It is worth learning properly.

Why an independent lab report matters, and where its usefulness ends

When you buy research compounds wholesale, you are buying a claim about molecular identity and purity that you cannot evaluate by eye. Powder looks like powder. A third-party analytical report exists to convert that claim into something measurable by a party with no financial stake in the outcome.

That is the value. The limit is equally important, and most buyers miss it. A lab report describes one sample, submitted by one party, on one date. It does not certify the supplier as a company. It does not confirm that the vial arriving at your door came from the same production run as the tested sample. It does not vouch for storage, handling, or shipping conditions after the sample left. And it says nothing about how the compound may be lawfully sold or used in your jurisdiction — that question belongs to your attorney, not to a chromatogram.

So treat a report as evidence about a batch, not as a character reference for a vendor. The vetting question is never just is this report real but is this report real, current, and about the thing I am actually buying.

How an analytical report is produced

Understanding the mechanism is what makes verification fast, because it tells you where the weak points are.

The sequence is straightforward. A submitter — usually the manufacturer, distributor, or a buyer doing their own due diligence — sends a physical sample to the laboratory and requests specific tests. The lab logs the sample, assigns it an internal identifier, runs the requested analyses, and issues a report recording the sample description as provided, the test methods used, the results, and the date. The report is tied to that identifier.

Notice what the lab controls and what it does not. The lab controls the analysis. It does not control what the submitter chose to send, or how the submitter later describes the result. That single gap is responsible for almost every misleading report circulating in this market: a genuine document, honestly produced by a competent lab, describing a sample that has no traceable relationship to the inventory being sold.

This is also why who submitted the sample matters. A report commissioned by a distributor on its own production batch is more meaningful than one commissioned on a hand-picked sample of unknown origin, and less meaningful than an independently pulled sample. None of that is visible from a purity percentage. It is visible from the document metadata, the batch reference, and whether the supplier can tell you a coherent story about where the sample came from.

What the individual panels on a report describe

A report is only as informative as the tests requested. A single-panel report is not a full picture, and suppliers sometimes lean on that ambiguity. In broad terms, the panels a buyer sees most often cover:

• Purity by HPLC — high-performance liquid chromatography separates the sample's components and reports the target peak as a percentage of total detected material. This is the headline number most sellers quote.
• Identity by mass spectrometry — confirms the measured molecular mass is consistent with the compound named. Purity without identity is a weak claim: a sample can be very pure and still not be what the label says.
• Peptide content or net quantity — how much of the labelled compound is actually present in the vial, as distinct from salts, counter-ions, and residual moisture. Purity and content are different measurements and are frequently conflated.
• Sterility and endotoxin panels — microbiological and bacterial-endotoxin screening, relevant to laboratory handling standards.
• Residual solvents, heavy metals, and moisture — contamination and stability indicators.

When a supplier says a product is tested, ask which panels. The answer separates a serious operation from one buying a single cheap number for marketing purposes. Research into peptide chemistry generally indicates that impurity profiles matter as much as headline purity for consistency between batches, which is why multi-panel documentation is the more meaningful signal.

Working through the verification, step by step

Do these in order. Stop at the first failure.

A few practical notes. Screenshots and cropped images are the most common way a genuine report is made unverifiable — always ask for the complete document. Compare the full page against what the lab's system returns, not just the summary line. And if a supplier's answer to can I verify this at the lab is friction rather than a reference number, you already have your answer.

The failure modes this process is designed to catch

There are four patterns worth naming, because each one is defeated by a different checkpoint above.

Report reuse. A single legitimate analysis presented as documentation for every batch sold thereafter. Caught by the date and batch checks.

Batch drift. The tested sample was real; the inventory shipping today came from a later, untested run. Caught by batch matching, and by asking whether testing happens per batch or once per product.

Document alteration. Numbers or headers edited on an otherwise genuine PDF. Caught only by resolving the identifier through the lab, which is why step two is not optional.

Selective disclosure. Real testing, honestly reported, but only the flattering panels are shown — or documentation is treated as a paid extra rather than something published alongside the product. Caught by asking which panels were run and whether reports are openly available before purchase.

That last pattern deserves emphasis, because it is a business-model tell rather than a document problem. Hidden wholesale pricing, testing described in general terms with nothing verifiable behind it, and analytical reports released only after a deposit are all indicators that documentation is being treated as a sales instrument. Suppliers confident in their results publish them.

The compliance questions to take to your own advisers

This section is informational and is not legal advice. Verifying a lab report answers a question about chemistry, not about lawfulness — and the two are routinely confused in this market.

Before you stock anything, sit down with your attorney and, where relevant, your state licensing board, and get answers to questions rather than assumptions: How are research-use-only compounds classified for the purposes of my business activity, and who decides that? What does my licence or registration actually authorise me to hold, label, or resell? What labelling and record-keeping obligations attach to inventory of this kind? Does my professional board take any position that constrains how a business like mine may handle these products? What documentation would I need to produce if asked?

None of those has a single national answer, and none of them should be resolved from a supplier's website, including this one. Requirements differ by jurisdiction and by the nature of your entity, so treat every general statement you read — here or anywhere else — as a prompt for your counsel rather than a conclusion. Research compounds are not approved drugs and are not for human consumption; how that framing interacts with your licence is a question for your own advisers.

What Real Peptides does differently

Real Peptides operates its Wholesale Partner Program on the assumption that a buyer will check the paperwork rather than trust a claim.

Compounds in the catalog are held to 99%+ HPLC purity, with multi-panel batch testing rather than a single purity figure carried forward indefinitely. Certificates of analysis are publicly verifiable — a prospective partner can read the lab results before applying, at no cost and without a deposit, and can run the verification sequence described above against them. Documentation is not sold separately or released only to closed accounts, which removes the most common obstacle to real due diligence.

Fulfillment is handled from within the United States, with a stated 5–7 day fulfillment window, and the wholesale application is a three-step process rather than an open-ended negotiation. Pricing tiers are presented to applicants directly instead of being quoted case by case behind a contact form. The same testing and documentation standard applies across the range, including the popular research peptides collection that most new partners build an initial order around. All products are supplied for laboratory and research use only.

If you are a licensed operator, clinic, telehealth business, or reseller and your counsel has confirmed that stocking research-use-only compounds fits your model, the application is where to start — bring the verification checklist above and use it on the published results before you commit to anything.

More detail on tiers and terms is available on the wholesale peptides program page, and qualified businesses can apply for a wholesale account directly.